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Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene product pVHL is the cause of inherited VHL disease and is
associated with sporadic kidney cancer. pVHL is found in a multiprotein complex with elongins B/C, Cul2, and Rbx1 forming an E3
ubiquitin ligase complex called VEC. This modular enzyme targets the α subunits of hypoxia-inducible factor (HIF) for ubiquitin-
mediated destruction. Consequently, tumour cells lacking functional pVHL overproduce the products of HIF-target genes such
as vascular endothelial growth factor (VEGF), which promotes angiogenesis. This likely accounts for the hypervascular nature of
VHL-associated neoplasms. Although pVHL has been linked to the cell-cycle, diﬀerentiation, and the regulation of extracellular
matrix assembly, microenvironment pH, and tissue invasiveness, this review will focus on the recent insights into the molecular
mechanisms governing the E3 ubiquitin ligase function of VEC.
INTRODUCTION
Studies of tumour suppressor genes responsible for rare
inherited cancer syndromes have revealed fundamental pro-
cesses in cell biology as well as the molecular origins
and pathogenesis of familial and sporadic forms of cancer.
Germline mutations in the von Hippel-Lindau (VHL)t u -
mour suppressor gene cause VHL disease, which is charac-
terized by the development of tumours in multiple organs
including the central nervous system (CNS), retina, adrenal
gland, and kidney [1, 2]. Although the incidence of VHL
disease is infrequent with an approximate incidence of 1 in
40,000individuals,bi-allelicinactivationoftheVHLgenehas
been documented in a majority of sporadic cerebellar hae-
mangioblastomas and renal clear cell carcinomas (RCC) [1].
RCC is the most common form of kidney cancer and is the
main cause of death in VHL patients [3].
CLONING OF THE VHL GENE
Chromosome 3p deletions are common in a variety of
solid tumours including renal carcinomas [4, 5]. Further-
more,severalstudiesidentiﬁedkindredswithearly-onset,bi-
lateral, and multifocal RCCs having germline translocations
of 3p to chromosomes 6, 8, or 11 [6, 7, 8]. In an eﬀort to
isolate the kidney cancer-susceptibility gene on chromosome
3p, scientists studied the hereditary kidney cancer associated
withVHLdisease,supposingthattheVHLgenemaybeasso-
ciatedwiththenonhereditaryformofkidneycancer.In1988,
Seizinger and colleagues used genetic linkage analysis to map
the VHL gene to a 6 to 8 centimorgan (cM) region of chro-
mosome 3p25 to 3p26 [9]. The putative VHL locus was then
narrowed to a 4cM interval by multipoint linkage analysis,
and pulse-ﬁeld gel electrophoresis was subsequently used to
further demarcate the minimal genomic region commonly
deletedamongunrelatedVHLkindreds[10,11].Armedwith
thisinformation,LatifandcolleaguesclonedtheVHLgenein
1993 [12].
VHL GENOTYPE-PHENOTYPE CORRELATIONS
The detection of intragenic mutations that segregated
with the disease in VHL kindreds conﬁrmed the authenticity
of the VHL gene. Furthermore, tumour-derived VHL gene
mutations have been identiﬁed throughout the VHL open
reading frame with the exception of the sequences encoding
theﬁrst54aminoacids[1,2].Despitethemutationalhetero-
geneity, striking correlations between certain germline mu-
tations and speciﬁc clinical manifestations of the disease are
emerging [1, 2]. Such genotype-phenotype correlations have
led to the classiﬁcation of the VHL disease into subcategories
depending on their propensity to develop phaeochromocy-
toma: Type 1 families have a low risk and Type 2 families
have a high risk of developing phaeochromocytoma. Type 2
is further subdivided into 2a (low risk of renal carcinoma),
2b(highriskofrenalcarcinoma),and2c(developexclusively
phaeochromocytoma without the other stigmata of the dis-
ease). Germline mutations associated with Type 1 disease are
usually deletions, microinsertions, and nonsense mutations,
whereas those mutations associated with Type 2 disease are
almost invariably missense mutations [13].
VEC MULTIPROTEIN COMPLEX
Neither the primary nucleotide nor the amino acid se-
quence of pVHL had any signiﬁcant homology to proteins132 S. K. Leung and M. Ohh 2:3 (2002)
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Figure 1. Comparison between the modular SCF and VEC complexes. SCF complex is composed of Skp1, Cdc53, Rbx1, and an F-box protein. Substrate
speciﬁcity is conferred by the F-box protein. For example, SCFSkp2 in concert with E2 ubiquitin-conjugating enzyme Cdc34 selectively targets the phospho-
rylated p27, as well as E2F-1 and Cyclin E, for ubiquitination. VEC complex is composed of Skp1-like elongin C, Cdc53 homologue Cul2, common Rbx1,
ubiquitin-like elongin B and an F-box protein pVHL. The SCF-like VEC complex in concert with a cognate E2 targets prolyl hydroxylated HIFα subunits for
ubiquitylation. NEDD8 conjugation to Cul1 or Cul2 enhances the E3 activity of both SCF and VEC complexes. Replacement of the F-box protein pVHL with
SOCS1 forms SEC that speciﬁcally targets VAV or Tel-Jak. B represents elongin B; C represents elongin C; S represents Skp1; R represents Rbx1; N represents
NEDD8.
with known functions. Thus, to discern the function(s) of
pVHL, several groups independently sought to identify the
cellular proteins that bound to pVHL, with the supposi-
tion that pVHL-associated proteins might have identiﬁable
functions. It is now evident that pVHL forms a multipro-
tein complex (VEC) with elongin B, elongin C, Cullin (Cul)
2, and Rbx1 (also called ROC1 or Hrt1) [14]. Remarkably,
the VEC complex bears striking structural homology with
a known class of E3 ubiquitin ligases called the SCF [14].
The E3 ubiquitin ligases target proteins for ubiquitylation,
which marks them for proteolysis by the 26S proteasome
(see Figure 1). The SCF complex consists of Skp1 (S-phase
kinase-associatedprotein1,suppressorofCdk-inhibitorpro-
teolysis and of kinetochore protein), Cdc53 or Cul1, Rbx1,
and a substrate-conferring F-box protein (so called because
of a collinear motif, ﬁrst identiﬁed in cyclin F) (Figure 1).
Cul2 bears signiﬁcant sequence and structural similari-
ties to the yeast Cullin,C d c 5 3[ 14]. Elongin C is homolo-
gous to Skp1 and performs an analogous Skp1-like role of
bridging the F-box protein to the rest of the complex [14].
Rbx1 is a common component of VEC and SCF complexes
[14]. The recently solved crystal structure of pVHL suggests
that it might have a function analogous to that of an F-box
protein [15]. Speciﬁcally, Pavletich and co-workers showed
that pVHL has two domains: an α domain and a β do-
main [15]. The α domain is essential for directly binding
elongin C, via the elongin B/C-binding motif, which loosely
resembles the F-box. Elongin C is associated with elongin B,
Cul2, and Rbx1. Thus, pVHL binding to elongin C via the α
domain promotes the nucleation of the VEC complex. The
β domain is predicted to function as a putative substrate-
docking site. Notably, disease-associated mutations found in
VHL kindreds map to the surface residues of α and β do-
mains, suggesting the importance of both domains in the tu-
mour suppressor function of pVHL. Thus, the structural ho-
mology between VEC and SCF complexes led to the notion
that pVHL may have a role in targeting certain protein(s) for
ubiquitin-mediated proteolysis (Figure 1).
VHL DISEASE-ASSOCIATED TUMOURS
AND VHL ANIMAL MODEL
A vital clue to the potential downstream substrate or
target of VEC came from the phenotypic observations of
VHL disease-associated tumours. That is, tumours associ-
ated with VHL disease, such as retinal angiomas, cerebel-
lar and spinal haemangioblastomas, and RCC, are known to
be hypervascular [14]. This condition has been attributed
primarily to the inability to suppress the expression of an-
giogenic peptides such as vascular endothelial growth fac-
tor (VEGF) that are normally induced by hypoxia [1, 14].
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functional pVHL express elevated levels of VEGF even un-
der normal oxygen tension [1, 2, 14]. Furthermore, Haase et
al generated conditional VHL knockout mice using the Cre-
loxP-mediated recombination, in which VHL can be inacti-
vated in a spatially and temporally controlled manner [16].
VHL −/− mice are not viable, precluding the study of pVHL
inactivationinadults[17].TargeteddisruptionofVHLinthe
liver resulted in severe steatosis, numerous blood-ﬁlled vas-
cularcavities,andfociofincreasedvascularizationwithinthe
hepatic parenchyma [16]. Notably, hypoxia-inducible mR-
NAs were markedly increased [16]. Thus, the conditional
mouse model for VHL disease underscores the signiﬁcance
of pVHL in the regulation of hypoxia-inducible genes.
HIF, THE FIRST TARGET OF VEC
A transcriptional complex called the hypoxia-inducible
factor (HIF) is a global regulator of oxygen-dependent gene
expression, including the aforementioned VEGF,w h i c hi s
upregulated during a cellular response to hypoxia [18, 19].
HIF is a heterodimeric transcriptional activator, composed
of α and β subunits, that binds DNA in a sequence-speciﬁc
manner. Whereas the α subunit is labile under normal oxy-
gen tension, the β subunit (also known as aryl hydrocar-
bon receptor nuclear translocator [ARNT]) is abundantly
expressed independently of oxygen tension. The α sub-
unit is subjected to ubiquitin-mediated degradation through
a stretch of residues referred to as the oxygen-dependent
degradation (ODD) domain. Hence, the regulation of HIF
is through the control of the unstable α subunit [18, 19].
Recently, Maxwell and colleagues observed that the α sub-
unit is stabilized in cells devoid of wild-type pVHL [20].
More importantly, they found that HIFα subunits are phys-
ically associated with pVHL [20]. These observations sug-
gested that the α subunits of HIF are the physiological targets
of pVHL.
TAGGING HIF WITH UBIQUITIN BY VEC
HIFα subunits are observed to bind directly to the pre-
dicted β domain of pVHL (Figure 1)[ 21, 22, 23]. Intrigu-
ingly, the ODD domain of HIFα subunit is both necessary
and suﬃcient for binding to pVHL [21, 22, 23]. Further-
more, pVHL is speciﬁcally required for the ubiquitylation
of HIFα subunits in vitro via the ODD domain [21, 22, 23].
Vascular tumour-derived mutations in the adapter α domain
or the substrate-docking β domain of pVHL abolished the
ubiquitylation of HIFα subunits, reiterating the concerted
requirement of pVHL to form (1) a multiprotein ubiquitin
ligase complex via elongin B/C-binding site within the α do-
main and (2) an eﬃcient recognition of HIFα subunits via
the β domain [22]. Hypoxia mimetics attenuated the ubiqui-
tin ligase activity of pVHL, reinforcing the notion that VEC
targets HIFα under the selective presence of oxygen [22].
It is now known that in the presence of oxygen, iron,
and oxoglutarate, HIFα is hydroxylated at highly conserved
proline residues, at positions 402 and 564 [24, 25, 26].
Epstein and co-workers found that in Caenorhabditis ele-
gans this process is accomplished by a novel EGL-9 dioxy-
genase [27]. There are three known mammalian EGL-9 ho-
mologues called PHD/HPH (prolyl hydroxylase domain-
containing protein, also referred to as HIF prolyl hydroxy-
lase)1,2,and3,thatperformananalogousfunction[27,28].
Importantly, hydroxylation of these proline residues is both
suﬃcient and necessary for binding to pVHL [24, 25, 26].
Thus, under normal oxygen tension or normoxia, pVHL in
an ubiquitin ligase complex selectively ubiquitylates the pro-
lyl hydroxylated HIFα [24, 25, 26]. Importantly, the disease-
associated pVHLs are unable to target the prolyl hydroxy-
lated HIFα for ubiquitin-mediated proteolysis under nor-
moxia [24]. Consequently, HIFα subunits and the down-
stream targets of HIF transcription factor are overexpressed
in cells lacking wild-type pVHL, irrespective of ambient oxy-
gen tension. These observations establish pVHL as a vital
component of a bona ﬁde E3 ubiquitin ligase complex that
m a r k sp r o l y lh y d r o x y l a t e dH I F α subunits with a polyubiq-
uitin chain for destructive targeting by the 26S proteasome
(see Figure 2).
It should be noted that prolyl hydroxylation as a post-
translational signal for recognition by an F-box protein
represents the ﬁrst exception to the current dogma of
phosphorylation-dependent recognition of target proteins
by the SCF complexes. Moreover, this raises the question
of what other protein-protein interactions and biochemical
processes are regulated by prolyl hydroxylation.
MODULATION OF VEC FUNCTION BY NEDD8
Despite our recent understanding of the oxygen-
dependent pathway that controls HIFα recognition by VEC,
the underlying mechanisms governing the actual activity
of VEC remain unclear. Genetic experiments with Sac-
charomyces cerevisiae, Schizosaccharomyces pombe,a n dAra-
bidopsis thaliana showed that an ubiquitin-like protein Rub-
1covalentlymodiﬁedCdc53andaﬀectedthefunctionofSCF
[29]. Likewise, the mammalian Rub-1 homologue NEDD8 is
also conjugatedtoCul1 in mammalianSCF and Cul2 in VEC
[30, 31]. The E2 NEDD8-conjugating enzyme, Ubc12, is re-
quired for the neddylation of Cullins including Cul1 and 2
[32, 33]. Moreover, the neddylation of Cul1 or 2 increases
the E3 ubiquitin ligase activities of SCF or VEC, respectively,
in vitro [34, 35, 36] and in vivo [34]. However, how Cul2
modiﬁcation by NEDD8 enhances the E3 activity of VEC is
unclear. One possibility is that NEDD8 conjugation to Cul2
increases the aﬃnity of Cul2 to E2 ubiquitin-conjugation en-
zyme. In support of this notion, Kawakami and colleagues,
recently demonstrated that NEDD8 conjugation to Cul1
enhances the aﬃnity of SCF to the E2 ubiquitin-conjugation
enzyme Ubc4 [37].
THE “VHL-PATHWAY” AND FUTURE DIRECTIONS
Recent insights into the molecular mechanisms gov-
erning the function of pVHL have provided signiﬁcant134 S. K. Leung and M. Ohh 2:3 (2002)
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Figure 2. Oxygen-dependent gene regulation via the “VHL-pathway.” In the presence of dioxygen, iron, and oxoglutarate, prolyl hydroxylases PHD/HPH 1,2,
and3hydroxylatetheαsubunit of HIFon proline residues 402and564.ThehydroxylatedHIFαsubunit is recognized by theVECcomplex for ubiquitylation.
I nr e d u c e do x y g e nt e n s i o n ,H I F α is no longer hydroxylated and thereby escapes ubiquitin-mediated proteolysis. HIFβ binds to the stable HIFα to form
HIF, which promotes the transcriptional activation of numerous hypoxia-inducible genes (HIGs). Protein synthesis of HIGs results in various physiological
responses to hypoxia. HRE represents hypoxia-responsive element; ECM represents extracellular matrix.
understanding of the “VHL-pathway.” In the presence of cel-
lulardioxygen,thenewlyidentiﬁeddioxygenases,PHD/HPH
1, 2, and 3, selectively hydroxylate the evolutionarily con-
served proline residues on HIFα subunits, which are then
selectively recognized by VEC via pVHL [27, 28]. VEC in
concert with a cognate E2 ubiquitin-conjugating enzyme
ubiquitylates the prolyl hydroxylated HIFα subunits for sub-
sequent destruction by the 26S proteasome. During hy-
poxia, HIFα is no longer modiﬁed by PHD/HPHs and con-
sequently escapes ubiquitin-mediated proteolysis. The now
stable HIFα dimerizes with HIFβ to form the transcrip-
tion factor HIF, which binds to hypoxia responsive ele-
ments to trigger the transcriptional activation of numer-
ous hypoxia-inducible genes, ultimately resulting in the syn-
thesis of proteins that mediate the physiological responses
to hypoxia (Figure 2). Thus, the “VHL-pathway” is intri-
catelytiedtotheoxygensensingmechanismsinmulticellular
organisms.
Further elucidation of the players that take part in the
“VHL-pathway” will undoubtedly beneﬁt the progress in the
development of pharmacological agents to treat not only
VHL patients but also those displaying tumours frequently
associated with VHL disease, such as vascular tumours of the
CNS and kidney. Moreover, the inability to maintain proper
oxygen homeostasis is the one unifying the pathophysiology
of stroke, cardiovascular diseases, chronic lung diseases, and
cancer, which represent the most common causes of death
in developed nations [38]. Thus, studies into the “VHL-
pathway”showgreatpromisetoaidinthedesignofsynthetic
drugs to block the progression of broad range of human dis-
eases.
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